First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

NCT01215344 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: VELCADE
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: DVT prophylaxis
DRUG: Bisphosphonates
DRUG: Liposomal doxorubicin
DRUG: Dexamethasone

Sponsor

Vanderbilt-Ingram Cancer Center